CRD007 for the Treatment of Duchenne Muscular Dystrophy, Becker Muscular Dystrophy and Symptomatic Carriers
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This is an investigation of the efficacy and safety of CRD007 in Duchenne Muscular Dystrophy
(DMD), Becker Muscular Dystrophy (BMD) and symptomatic carriers.